HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senetek acquisition

This article was originally published in The Rose Sheet

Executive Summary

Kinetin manufacturer has signed a letter of intent to acquire IGI, the makers of a patented micro-encapsulation dermal delivery technology called Novasome. Company expects to tap cross-selling opportunities between Kinetin skin care ingredient and Novasome and says the acquisition will diversify and strengthen its existing portfolio. Senetek will acquire IGI in a stock-for-stock transaction in which Senetek shareholders would receive 60% of the shares of a newly formed holding company and IGI shareholders would receive 40%. Agreement is subject to due diligence review and approval from the respective boards of directors and shareholders...

You may also be interested in...



Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

UK-Based GMDN Endorsed As US Preferred Method For Categorizing High-Risk Implants

While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?

US Substitution Rates Lower For Higher Cost Brands

Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.

UsernamePublicRestriction

Register

RS012578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel